Domperidone-Induced Tardive Dyskinesia and Withdrawal Psychosis in an Elderly Woman with Dementia (September)

  1. Jean-François Trudel, MD CSPQ FRCPC MSc, Professor6
  1. 1Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Quebec, Canada
  2. 2Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke
  3. 3Division of Neurology, Department of Medicine, Faculté de Médecine et des Sciences de la Santé and Research Centre on Aging, Université de Sherbrooke
  4. 4Geriatrics Service, Department of Medicine, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke
  5. 5Department of Psychiatry, Faculté de Médecine et des Sciences de la Santé, Sherbrooke
  6. 6Department of Psychiatry, Faculté de Médecine et des Sciences de la Santé, Sherbrooke
  1. *Correspondence: Jean-Francois.Trudel{at}USherbrooke.ca

Abstract

OBJECTIVE: To report a case of probable domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman.

CASE SUMMARY: A 75-year-old woman was first assessed for cognitive decline and personality changes. On clinical examination, diffuse choreoathetoid movements were noted. Chronic domperidone use seemed the most likely cause for the movement disorder and was abruptly discontinued. Within a few days, she developed a severe psychotic syndrome with Capgras delusions; the movement disorder continued unabated. Both the movement disorder and psychotic symptoms promptly remitted with risperidone treatment.

DISCUSSION: Domperidone has, on rare occasions, been associated with acute extrapyramidal syndromes, especially in young children, but, to our knowledge, this is the first case of domperidone-induced tardive dyskinesia and withdrawal psychosis, adverse effects associated with chronic central nervous system dopaminergic blockade. Domperidone is a dopamine D2 receptor antagonist that does not usually cross the blood-brain barrier. However, blood-brain barrier alterations occur with aging and dementia, which may explain central nervous system penetration of domperidone in our patient, diagnosed with probable frontotemporal dementia. The association was rated as probable on the Naranjo probability scale.

CONCLUSIONS: Chronic use of domperidone may, on rare occasions, induce neuropsychiatric syndromes similar to those seen with the use of antipsychotics. This may be more likely in situations in which the blood-brain barrier is damaged, as in vascular and degenerative dementias.

Footnotes